← All research
HPV-TXV · Complete
Target product profiles for therapeutic vaccines
Evaluating the impact of a range of potential HPV therapeutic vaccines with varying scale-up of existing preventive interventions in high-burden low- and middle-income countries (LMICs).
What we're tracking
- A therapeutic vaccine clearing 90% of virus and regressing 50% of high-grade lesions, reaching 70% of women aged 35-45 from 2030, could avert 1.2-2.2 million cervical cancer cases across nine high-burden LMICs over 30 years.
- Impact translates to 500,000-1.2 million cervical cancer deaths and 20-40 million DALYs averted.
- Impact is highly sensitive to vaccine characteristics, especially how long immune memory lasts, and to the pace of background screening and preventive vaccination scale-up.
Outputs
At a glance
- Themes